Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 4, July-August, p. 517–521

Publication type: original article

Language: English

Exonic Deletions in the NF1 Gene in Patients with Neurofibromatosis Type I from the Lower Silesian Region of Poland

Izabela Łaczmańska1,A,B,C,D,E,F,G, Małgorzata Szczepaniak1,B,C,F,G, Aleksandra Jakubiak1,B,C,F, Agnieszka Stembalska1,A,B,C,D,E,F

1 Department of Genetics, Wroclaw Medical University, Poland

Abstract

Background. Neurofibromatosis type I (NF1, Recklinghausen’s disease) is an autosomal dominant disorder characterized by the following clinical features: café au lait spots, neurofibromas, Lisch nodules, freckling of the axillary and inguinal regions, optic nerve gliomas, bone dysplasia and increased risk of certain tumors. NF1 is diagnosed on the basis of clinical criteria, while identifying the genetic background of the disease is important mainly for genetic counseling. NF1 genetic analysis is based on searching for NF1 exon deletions/duplications using Multiplex ligationdependent probe amplification (MLPA), searching for microdeletions of the critical region using fluorescence in situ hybridization (FISH), searching for point mutations by gene sequencing (in most cases) and analyzing mRNA.
Objectives. The aim of this study was to estimate the frequency of single and multi-exon deletions/duplications in the NF1 gene in Polish patients, and to evaluate the usefulness of MLPA as a cheap and easy method for NF1 molecular diagnosis, despite the fact that such changes may be found in only a small group of NF1 patients.
Material and Methods. The study included 65 patients suspected of NF1 or with recognized NF1 on the basis of clinical criteria. Cytogenetic analysis were carried out for all the patients, and for one patient with a translocation [46,XY,t(17;22)(q11.2;q11.2)], a FISH analysis was performed. All patients were tested for deletions/duplications in the NF1 gene using two MLPA kits for neurofibromatosis I.
Results. The MLPA analysis showed deletions in the NF1 gene in 7.7% of the cases (5/65).
Conclusion. The results indicate that an MLPA analysis may be performed in patients with a clinical diagnosis of NF1 or patients with suspected NF1 as an easy and inexpensive first molecular test, enabling the exclusion of about 7% of NF1 patients from expensive and time-consuming molecular diagnosis by DNA sequencing.

Key words

NF1, Recklinghausen’s disease, MLPA.

References (12)

  1. Dahan D, Fenichel GM, El-Said R: Neurocutaneous syndromes. Adolesc Med 2002, 13, 495–509.
  2. Griffiths S, Thompson P, Frayling I, Upadhyaya M: Molecular diagnosis of neurofibromatosis type 1: 2 years experience. Fam Cancer 2007, 6, 21–34.
  3. Ferner RE: Neurofibromatosis 1. EJHG 2007, 15, 131–138.
  4. Jett K, Friedman JM: Clinical and genetic aspects of neurofibromatosis 1. GeneTest Rev 2010, 1, 1–11.
  5. Trovó-Marqui AB, Tajara EH: Neurofibromin: a general outlook Clin Genet 2006, 70, 1–13.
  6. Valero MC, Martín Y, Hernández-Imaz E, Marina Hernández A, Meleán G, Valero AM, Javier Rodríguez-Álvarez F, Tellería D, Hernández-Chico C: A highly sensitive genetic protocol to detect NF1 mutations. J Mol Diagn 2011, 13, 113–122.
  7. De Luca A, Bottillo I, Dasdia MC, Morella A, Lanari V, Bernardini L, Divona L, Giustini S, Sinibaldi L, Novelli A, Torrente I, Schirinzi A, Dallapiccola B: Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe amplification. J Med Genet 2007, 44, 800–808.
  8. Wimmer K, Yao S, Claes K, Kehrer-Sawatzki H, Tinschert S, De Raedt T, Legius E, Callens T, Beiglböck H, Maertens O, Messiaen L: Spectrum of singleand multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes Cancer 2006, 45, 265–276.
  9. Gustashaw KM: Chromosome stains In: The AGT Cytogenetics Laboratory Manual. Barch MJ, Knusten T, Spurbeck J. Lippincot-Raven Publishers, Philadelphia 1997, 259–324.
  10. Shaffer LG, Slovak ML, Campbell LJ: ISCN 2009, An International System for Human Cytogenetic Nomenclature 2009. Karger, Basel 2009.
  11. DeBella K, Szudek J, Friedman JM: Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000, 105, 608–614.
  12. MRC Holland www.mrc-holland.com
© Wroclaw Medical University